When asked about any physical or internal impact post-vaccination, she bravely stated in front of the camera that she isn't having any problem so far.
On Monday, Zee News reporter Pooja Makkar became the first female journalist to get the indigenously developed coronavirus vaccine, Covaxin, in India. She was vaccinated at AIIMS, Delhi in the afternoon at 2 pm after the requisite tests. She remained under observation and shared her experience later.
Covaxin has been developed by Bharat Biotech in collaboration with ICMR and was approved by India's drug regulator on Sunday for emergency use.
Sharing her experience, she said that after five and a half hours, she has not felt any complication.
Pooja, who is a health reporter, added that she decided to undergo the vaccination as "it was necessary to instill confidence among common people that the vaccine is fully safe." When asked about any physical or internal impact post-vaccination, she bravely stated in front of the camera that she is not having any problem so far.
After the vaccination, she has been given a sheet to record her experience. She has also been provided with a helpline number to contact AIIMS in case she faces any complications or side-effects. As required, she will get another shot of Covaxin after 28 days.
The Drugs Controller General of India (DCGI) on Sunday provided emergency use approval of the two coronavirus vaccines.
While the country is rejoicing the nod to the vaccines, opposition parties have raised doubts on the approval granted to Bharat Biotech’s vaccine against Covid-19 while its third phase trial is still underway.
Covaxin is India’s first indigenous vaccine against Covid-19. It has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology. Congress is raising doubts on the efficacy of the Covaxin because it is indigenously developed because its leaders feel anything made in India lacks in some parameters and is not safe for use.
The made-in-India vaccine can be cheaper in terms of price, so the Congress and other opposition parties are suspicious of its efficacy and these parties now want to convey this suspicion to more and more people in a short time like a virus. They are doing this so that people who are infected with this suspected virus refuse to get a vaccine made in India.
Meanwhile, coming down heavily on critics expressing doubts about Covaxin, Bharat Biotech's managing director Dr Krishna Ella on Monday slammed the critics for targeting Indian clinical trials and asked why they were not questioning the UK clinical trials of another vaccine.
Ella said that the company does not deserve the backlash it is receiving in the light of India's drugs regulator granting its coronavirus vaccine Covaxin approval for emergency use.
"Don't accuse us of inexperience. We are a global company... have manufactured 16 vaccines," he said, highlighting that "200% honest" clinical trials were conducted.
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
 "COVID-19 covaxin Pooja Makkar")
){kind=small}
){kind=small}
){kind=small}
){kind=small}
)
){kind=small}
){kind=small}
)
)
)
)
)
){kind=small}
){kind=small}
){kind=small}
){kind=small}